Erasca’s IPO leads the way as three cancer biotechs raise $534M for clinical trials
Cancer drug developer Erasca, whose mission is to "erase cancer," has raised $300 million from its IPO. The clinical-stage biotech addresses a single elusive cancer target; it has multiple programs taking multiple approaches, two of them in human testing and the rest on track to join them. Cancer biotechs Imago BioSciences and TScan Therapeutics also priced IPOs.
